Crestovo starts Phase II trial of CP101 to treat CDI

Crestovo LLC (Cambridge, Mass.) began the Phase II PRISM 3 trial evaluating CP101 to prevent recurrent Clostridium difficile infection. The double-blind, placebo-controlled, U.S. trial is evaluating two doses of CP101 in about 240 patients.

The primary endpoints are sustained clinical cure rate and safety. Secondary endpoints include sustained clinical cure rate by C. difficile subtype and at week 24 and time to first recurrence of C. difficile...